Branded drugs lose almost 90% share to generics within a year
This article was originally published in Scrip
Executive Summary
Branded drugs with sales greater than $100m have managed to maintain a robust 12.6 years of market exclusivity before experiencing generic competition, but when it arrives, generic competition is more intense than it was 10-15 years ago. These are the main conclusions of a paper authored by Duke University Department of Economics professor Henry Grabowski, in collaboration with Genia Long and Richard Mortimer of Analysis Group, a Boston-based economic, financial and strategy consultancy, published in the March edition of the Journal of Medical Economics (read the free report here bit.ly/1mQ9Rqb ).